Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer

NCT01301911 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT01301911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01301911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2011
Completion date
November 30, 2012
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer